TCRT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:10):

Stats
Šios dienos apimtis	11 884.00
Vidutinė apimtis	77 422.00
Rinkos kapitalizacija	22.26M
EPS	$0 ( 2024-04-02 )
Kita pelno data	( $-0.450 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.0190 (1.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Groenewald Ferdinand	Buy	0
2024-01-20	Hogue Dale Curtis Jr.	Buy	600 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	150 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	41 667	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	0

INSIDER POWER
96.77
Last 87 transactions
Buy: 16 191 500 \| Sell: 2 243 866

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: 0.88 (strong)

Signal:(64.148) Same movement expected

Alaunos Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
WISA	0.942
ALZN	0.935
TTCF	0.935
KVSB	0.932
ALLO	0.931
GH	0.927
ADSE	0.926
AGFY	0.925
COMT	0.925
INFI	0.924

10 Labiausiai neigiamai susiję koreliacijos
IBEX	-0.937
ISIG	-0.92
STAY	-0.914
RNLC	-0.913
CCRC	-0.912
SLGN	-0.91
USLB	-0.904
SEDG	-0.903
XOMAO	-0.903
VLYPO	-0.894

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Alaunos Therapeutics, Koreliacija - Valiuta/Žaliavos

-0.34
( neutral )

-0.55
( weak negative )

0.00
( neutral )

-0.07
( neutral )

0.12
( neutral )

-0.18
( neutral )

Alaunos Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$5 000.00
Bruto pelnas:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

FY	2023
Pajamos:	$5 000.00
Bruto pelnas:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

FY	2022
Pajamos:	$2.92M
Bruto pelnas:	$163 000 (5.58 %)
EPS:	$-2.60

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Alaunos Therapeutics,

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.